TG Therapeutics, Inc. (TGTX) compared with its closest peers (INSM, MIRM, BBIO, TVTX, EBS): P/E 18.7 vs industry 15.1. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Insmed, Mirum Pharmaceuticals, BridgeBio Pharma, Travere Therapeutics, Emergent BioSolutions, Opko Health, Catalyst Pharmaceuticals, Ionis Pharmaceuticals, Supernus Pharmaceuticals and Ultragenyx Pharmaceutical share TG Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Insmed Incorporated (INSM) | $28.26B | — |
| Mirum Pharmaceuticals, Inc. (MIRM) | $6.38B | — |
| BridgeBio Pharma, Inc. (BBIO) | $14.17B | — |
| Travere Therapeutics, Inc. (TVTX) | $6.15B | — |
| Emergent BioSolutions Inc. (EBS) | $319.18M | 13.3 |
| Opko Health, Inc. (OPK) | $1.17B | — |
| Catalyst Pharmaceuticals, Inc. (CPRX) | $3.85B | 17.4 |
| Ionis Pharmaceuticals, Inc. (IONS) | $9.00B | — |
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.42B | — |
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.42B | — |
| Stock P/E | 18.7 |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| vs Sector | -3.8% |
| vs Industry | 23.4% |
TGTX overview · TGTX earnings · TGTX financials · TGTX KPIs · TGTX documents · TGTX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.